CA2959003A1 - Use of cysteamine in treating infections caused by yeasts/moulds - Google Patents

Use of cysteamine in treating infections caused by yeasts/moulds Download PDF

Info

Publication number
CA2959003A1
CA2959003A1 CA2959003A CA2959003A CA2959003A1 CA 2959003 A1 CA2959003 A1 CA 2959003A1 CA 2959003 A CA2959003 A CA 2959003A CA 2959003 A CA2959003 A CA 2959003A CA 2959003 A1 CA2959003 A1 CA 2959003A1
Authority
CA
Canada
Prior art keywords
spp
peptide
composition
cysteamine
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2959003A
Other languages
English (en)
French (fr)
Inventor
Deborah O'neil
Vanessa DUNCAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Publication of CA2959003A1 publication Critical patent/CA2959003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2959003A 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds Abandoned CA2959003A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462053523P 2014-09-22 2014-09-22
US62/053,523 2014-09-22
GBGB1416727.4A GB201416727D0 (en) 2014-09-22 2014-09-22 Use
GB1416727.4 2014-09-22
PCT/GB2015/052714 WO2016046524A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Publications (1)

Publication Number Publication Date
CA2959003A1 true CA2959003A1 (en) 2016-03-31

Family

ID=51869299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959003A Abandoned CA2959003A1 (en) 2014-09-22 2015-09-21 Use of cysteamine in treating infections caused by yeasts/moulds

Country Status (14)

Country Link
EP (1) EP3197476A1 (ja)
JP (1) JP2017532317A (ja)
KR (1) KR20170052613A (ja)
CN (1) CN106687140A (ja)
AU (1) AU2015323566B2 (ja)
BR (1) BR112017005272A2 (ja)
CA (1) CA2959003A1 (ja)
GB (1) GB201416727D0 (ja)
MX (1) MX2017003550A (ja)
NZ (1) NZ730092A (ja)
RU (1) RU2017108196A (ja)
SG (1) SG11201701648UA (ja)
WO (1) WO2016046524A1 (ja)
ZA (1) ZA201701330B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000202A (es) 2015-07-02 2018-06-27 Horizon Orphan Llc Analogos de cisteamina resistentes a la ado y sus usos.
JP2020505359A (ja) * 2017-01-25 2020-02-20 アデア ファーマシューティカルズ,インコーポレイテッド システアミンプロドラッグ
WO2018224813A1 (en) * 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
EP3866775A1 (en) * 2018-10-17 2021-08-25 Novabiotics Limited Dosage regime
CN110551637B (zh) * 2019-09-03 2020-11-27 黑龙江省农业科学院植物保护研究所 一种来自黄芪根部的高效抑制番茄灰霉病菌的棘壳孢菌及其应用
CN110859950B (zh) * 2019-11-25 2021-08-10 武汉大学 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
ATE479704T1 (de) * 2004-08-18 2010-09-15 Novabiotics Ltd Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
JP2006347990A (ja) * 2005-06-20 2006-12-28 Pola Chem Ind Inc 爪用の抗真菌医薬組成物
JP2006347989A (ja) * 2005-06-20 2006-12-28 Pola Chem Ind Inc 爪用の抗真菌医薬組成物
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2464334A4 (en) * 2009-08-13 2014-03-26 Moberg Derma Ab COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTION OF NAILS
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
MX2017003550A (es) 2017-07-28
KR20170052613A (ko) 2017-05-12
EP3197476A1 (en) 2017-08-02
WO2016046524A1 (en) 2016-03-31
JP2017532317A (ja) 2017-11-02
NZ730092A (en) 2018-05-25
AU2015323566B2 (en) 2018-03-22
AU2015323566A1 (en) 2017-04-06
RU2017108196A3 (ja) 2019-06-19
GB201416727D0 (en) 2014-11-05
RU2017108196A (ru) 2018-10-24
BR112017005272A2 (pt) 2017-12-12
SG11201701648UA (en) 2017-04-27
CN106687140A (zh) 2017-05-17
ZA201701330B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
AU2015323566B2 (en) Use of cysteamine in treating infections caused by yeasts/moulds
AU2018202201B2 (en) Peptides and their use
AU2017201670B2 (en) A composition comprising an antibiotic and a dispersant or an anti-adhesive agent
JP5020078B2 (ja) ペプチド
US20160106689A1 (en) Use
IL240686A (en) Preparations containing cyclic peptides containing adjacent arginine residues
WO2016046523A1 (en) Use of cystamine for treating bacterial and fungal infections
WO2010139539A1 (de) Pharmazeutische zusammensetzungen, enthaltend antifungale peptide
US20160102052A1 (en) Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
WO2017212239A1 (en) Treatment of drug-resistant microbial infections
AU2011235933B2 (en) Antimicrobial peptides comprising an arginine- and/or lysine-containing motif

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200923